State of Alaska Department of Revenue increased its position in Pfizer Inc. (NYSE:PFE) by 11.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 371,887 shares of the biopharmaceutical company’s stock after buying an additional 37,647 shares during the period. Pfizer comprises 1.4% of State of Alaska Department of Revenue’s investment portfolio, making the stock its 12th largest position. State of Alaska Department of Revenue’s holdings in Pfizer were worth $13,093,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the company. Oliver Luxxe Assets LLC increased its stake in Pfizer by 429.0% in the first quarter. Oliver Luxxe Assets LLC now owns 100,305 shares of the biopharmaceutical company’s stock worth $2,973,000 after buying an additional 81,343 shares in the last quarter. Howard Capital Management increased its stake in Pfizer by 1.4% in the first quarter. Howard Capital Management now owns 85,190 shares of the biopharmaceutical company’s stock worth $2,525,000 after buying an additional 1,162 shares in the last quarter. Montrusco Bolton Investments Inc. increased its stake in Pfizer by 32.2% in the first quarter. Montrusco Bolton Investments Inc. now owns 14,769 shares of the biopharmaceutical company’s stock worth $438,000 after buying an additional 3,599 shares in the last quarter. Dividend Asset Capital LLC increased its stake in Pfizer by 31.5% in the first quarter. Dividend Asset Capital LLC now owns 13,844 shares of the biopharmaceutical company’s stock worth $410,000 after buying an additional 3,315 shares in the last quarter. Finally, V Wealth Management LLC purchased a new stake in Pfizer during the first quarter worth $272,000. 69.66% of the stock is owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Pfizer Inc. (NYSE:PFE) traded up 0.15% during trading on Monday, hitting $33.61. The company’s stock had a trading volume of 16,383,660 shares. Pfizer Inc. has a 12 month low of $28.25 and a 12 month high of $37.39. The firm has a market cap of $203.87 billion, a P/E ratio of 29.80 and a beta of 0.86. The firm has a 50 day moving average of $34.25 and a 200 day moving average of $34.28.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.62 by $0.02. The company earned $13.10 billion during the quarter, compared to the consensus estimate of $13.01 billion. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. Pfizer’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 EPS. Equities research analysts predict that Pfizer Inc. will post $2.46 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Friday, November 11th will be given a $0.30 dividend. The ex-dividend date of this dividend is Tuesday, November 8th. This represents a $1.20 dividend on an annualized basis and a yield of 3.57%. Pfizer’s payout ratio is 95.24%.

A number of research firms have recently weighed in on PFE. Argus reissued a “buy” rating and set a $39.00 target price on shares of Pfizer in a report on Sunday, August 28th. Sanford C. Bernstein reissued an “outperform” rating on shares of Pfizer in a report on Monday, September 26th. Jefferies Group reissued a “buy” rating and set a $42.00 target price (up previously from $41.00) on shares of Pfizer in a report on Tuesday, June 14th. Vetr downgraded Pfizer from a “strong-buy” rating to a “buy” rating and set a $37.28 price target for the company. in a research note on Tuesday, June 28th. Finally, Citigroup Inc. reaffirmed a “neutral” rating and issued a $37.00 price target on shares of Pfizer in a research note on Wednesday, August 3rd. Ten analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Pfizer presently has an average rating of “Buy” and a consensus price target of $38.78.

Pfizer Company Profile

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

5 Day Chart for NYSE:PFE

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.